additive with GLP-1 Semaglutide Established CV outcomes Tirzepatide Highest single-agent obesity efficacy Retatrutide Triple-agonist mechanism Numbers reflect published Phase 3 endpoints where available
Consequently, many clinicians combine both therapies to achieve synergistic effects, particularly in complex or chronic tendon injuries
Hence, pathways and mechanisms need to be investigated for possible pharmacological intervention
[21] [22] [23] [24] [25] Anemia may present with a number of further common symptoms, [21] [26] including hair thinning and loss, early greying of the hair, mouth ulcers, bleeding gums, [22] angular cheilitis, a look of exhaustion with pale and dehydrated or cracked lips and dark circles around the eyes, as well as brittle nails
They may provide incremental benefits when used appropriately and under supervision